Beclin-1-p53 interaction is crucial for cell fate determination in embryonal carcinoma cells

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 11, 2014, Pages 2275-2286

  Tripathi, Rakshamani ^a   Ash, Dipankar ^a   Shaha, Chandrima ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Apoptosis; Autophagy; Beclin 1; Cisplatin; Embryonal carcinoma cells; P53

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; CISPLATIN; MEMBRANE PROTEIN; PROTEIN BCL 2; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL; APOPTOSIS; AUTOPHAGY; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL SURVIVAL; DRUG SCREENING; EMBRYONAL CARCINOMA STEM CELL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MOUSE; PATHOLOGY; PROTEIN PROTEIN INTERACTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL DIFFERENTIATION; CELL SURVIVAL; CISPLATIN; EMBRYONAL CARCINOMA STEM CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE PROTEINS; MICE; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911376426     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12386     Document Type: Article

References (41)

1. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol. 2007; 8: 741-52.
2. Su M, Mei Y, Sinha S. Role of the crosstalk between autophagy and apoptosis in cancer. J Oncol. 2013; 2013: 102735.
3. Maiuri MC, Tasdemir E, Criollo A, et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 2009; 16: 87-93.
4. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991; 253: 49-53.
5. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin-1. Nature. 1999; 402: 672-6.
6. Galluzzi L, Kroemer G. Common and divergent functions of Beclin 1 and Beclin 2. Cell Res. 2013; 23: 341-2.
7. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 2007; 7: 165-7.
8. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014; 25: 304-17.
9. Bharatham N, Chi SW, Yoon HS. Molecular basis of Bcl-X(L)-p53 interaction: insights from molecular dynamics simulations. PLoS ONE. 2011; 6: e26014.
10. Keller DM, Zeng SX, Lu H. Interaction of p53 with cellular proteins. Methods Mol Biol. 2003; 234: 121-33.
11. Maiuri MC, Le TG, Criollo A, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J. 2007; 26: 2527-39.
12. Abrahamsen H, Stenmark H, Platta HW. Ubiquitination and phosphorylation of Beclin 1 and its binding partners: tuning class III phosphatidylinositol 3-kinase activity and tumor suppression. FEBS Lett. 2012; 586: 1584-91.
13. Marquez Rebecca T, Liang Xu. Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res. 2012; 2: 214-21.
14. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435: 677-81.
15. Davids MS, Letai A. ABT-199: taking dead aim at BCL-2. Cancer Cell. 2013; 23: 139-41.
16. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82: 373-428.
17. Watson IR, Irwin MS. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia. 2006; 8: 655-66.
18. Shi CS, Kehrl JH. TRAF6 and A20 regulate lysine 63-linked ubiquitination of Beclin-1 to control TLR4-induced autophagy. Sci Signal. 2010; 3: ra42.
19. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005; 18: S61-79.
20. Abada PB, Howell SB. Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. PLoS ONE. 2014; 9: e87444.
21. Tripathi R, Samadder T, Gupta S, et al. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther. 2011; 10: 255-68.
22. Chu CT, Plowey ED, Dagda RK, et al. Autophagy in neurite injury and neurodegeneration: in vitro and in vivo models. Methods Enzymol. 2009; 453: 217-49.
23. Ni HM, Bockus A, Wozniak AL, et al. Dissecting the dynamic turnover of GFP-LC3 in the autolysosome. Autophagy. 2011; 7: 188-204.
24. Yang YP, Hu LF, Zheng HF, et al. Application and interpretation of current autophagy inhibitors and activators. Acta Pharmacol Sin. 2013; 34: 625-35.
25. Bjørkøy G, Lamark T, Pankiv S, et al. Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol. 2009; 452: 181-97.
26. Prabhu V, Srivastava P, Yadav N, et al. Resveratrol depletes mitochondrial DNA and inhibition of autophagy enhances resveratrol-induced caspase activation. Mitochondrion. 2013; 13: 493-9.
27. Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001; 70: 503-33.
28. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, et al. AMPK-mediated autophagy inhibits apoptosis in cisplatin-treated tumour cells. J Cell Mol Med. 2009; 13: 3644-54.
29. Yamamoto A, Tagawa Y, Yoshimori T, et al. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998; 23: 33-42.
30. Liu B, Bao JK, Yang JM, et al. Targeting autophagic pathways for cancer drug discovery. Chinese J Cancer. 2013; 32: 113-20.
31. Fu LL, Cheng Y, Liu B. Beclin-1: autophagic regulator and therapeutic target in cancer. Int J Biochem Cell Biol. 2013; 45: 921-4.
32. Guillemain I, Gaboyard S, Fontès G, et al. Differential expression of Bcl-2-related proteins in differentiating NT2 cells. NeuroReport. 2000; 11: 1421-5.
33. Pattingre S, Tassa A, Qu X, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122: 927-39.
34. Lutzker SG, Levine AJ. A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nat Med. 1996; 7: 804-10.
35. Altman BJ, Rathmell JC. Metabolic stress in autophagy and cell death pathways. Cold Spring Harb Perspect Biol. 2012; 4: a008763.
36. Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011; 147: 223-34.
37. Platta HW, Abrahamsen H, Thoresen SB, et al. Nedd4-dependent lysine-11-linked polyubiquitination of the tumour suppressor Beclin 1. Biochem J. 2012; 441: 399-406.
38. Yang ZJ, Chee CE, Huang S, et al. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011; 10: 1533-41.
39. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012; 11: 709-30.
40. White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer. Clin Cancer Res. 2009; 15: 5308-16.
41. Eisenberg-Lerner A, Kimchi A. The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis. 2009; 14: 376-91.